A Phase 1/2 Trial of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Thai Infants
Abstract:
The Walter Reed Army Institute of Research WRAIR has produced a tetravalent live-attenuated dengue vaccine that has been well tolerated and immunogenic in U.S. adults and Thai children. As infants are considered by many as an important age group for vaccination in dengue-endemic countries, we evaluated the vaccine in Thai flavivirus-na ve infants who are at risk for dengue.
Security Markings
DOCUMENT & CONTEXTUAL SUMMARY
Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.
RECORD
Collection: TR